Joseph Maroon - Mylan N Insider

Mylan N V -- USA Stock  

USD 41.67  0.06  0.14%

Independent Director

Dr. Joseph C. Maroon, M.D., is an Independent Director of Mylan Inc., since 2003. Dr. Maroon is currently Professor, Heindl Scholar in Neuroscience and Vice Chairman of the Department of Neurosurgery, University of Pittsburgh Medical Center, and has held other positions at UPMC since 1998. He has also served as the team neurosurgeon for the Pittsburgh Steelers since 1981. From 1995 to 1998, Dr. Maroon was Professor and Chairman of the Department of Surgery at Allegheny General Hospital, and from 1984 to 1999 he was Professor and Chairman of the Department of Neurosurgery at Allegheny General Hospital. Dr. Maroon has earned numerous awards for his contributions to neurosurgery from various national and international neurological societies throughout his career, and patients travel from all over the world to seek his care.
Age: 73  Director Since 2003      
44 17 0785 3000

Joseph Maroon Latest Insider Activity

Management Efficiency

The company has Return on Asset of 3.79 % which means that on every $100 spent on asset it made $3.79 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 6.92 % implying that it generated $6.92 on every 100 dollars invested.
The company has 14.72 B in debt with debt to equity (D/E) ratio of 110.7 . This implies that the company may be unable to create cash to meet all of its financial commitments. Mylan N V has Current Ratio of 1.43 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives


David AltshulerVertex Pharmaceuticals Incorpor
Deborah NeffBio Rad Laboratories Inc
Glenn TiltonAbbott Laboratories
Ron TaylorAllergan plc
David GreenwayVertex Pharmaceuticals Incorpor
Samuel ScottAbbott Laboratories
Alan GarberVertex Pharmaceuticals Incorpor
Edward LiddyAbbott Laboratories
Michael HyattEndo International plc
Ronald TaylorAllergan plc
Nesli BasgozAllergan plc
Shane CookeEndo International plc
Peter McDonnellAllergan plc
Louis DrapeauBio Rad Laboratories Inc
James FarrellAbbott Laboratories
Phebe NovakovicAbbott Laboratories
Michael GallagherAllergan plc
Margaret McGlynnVertex Pharmaceuticals Incorpor
Jill SmithEndo International plc
Daniel StarksAbbott Laboratories
Sally BlountAbbott Laboratories

Entity Summary

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide. Mylan N.V. was founded in 1961 and is based in Hatfield, the United Kingdom. Mylan N operates under Drugs - Generic classification in USA and traded on NASDAQ exchange. It employs 35000 people.Mylan N V (MYL) is traded on NASDAQ in USA. It is located in UNITED KINGDOM and employs 35,000 people. Mylan N is listed under Pharmaceutical Products category by Fama And French industry classification.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Mylan N V to your portfolio

Top Management

Mylan N V Leadership Team
Anthony Mauro, President
Joseph Maroon, Director
Kris King, VP
Heather Bresch, CEO
Melina Higgins, Director
Mark Parrish, Director
Kenneth Parks, CFO
Rodney Piatt, Chairman, CPA
Rajiv Malik, President
John Sheehan, President, CPA
Dennis Zeleny, Executive
JoEllen Dillon, Director
Neil Dimick, Director
Sjoerd Vollebregt, Director
Douglas Leech, Director
Robert Cindrich, Director
Wendy Cameron, Director
Rakesh Bamzai, President, MBA
Robert Coury, Chairman
Daniel Gallagher, Executive
Randall Vanderveen, Director

Stock Performance

Mylan N Performance Indicators